Tudor Investment Corp ET AL Raises Stock Position in NovoCure Limited $NVCR

Tudor Investment Corp ET AL boosted its holdings in NovoCure Limited (NASDAQ:NVCR) by 140.6% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 606,070 shares of the medical equipment provider’s stock after buying an additional 354,216 shares during the period. Tudor Investment Corp ET AL owned 0.54% of NovoCure worth $7,830,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of NVCR. Quantbot Technologies LP lifted its position in shares of NovoCure by 163.6% in the third quarter. Quantbot Technologies LP now owns 195,515 shares of the medical equipment provider’s stock worth $2,526,000 after buying an additional 121,354 shares in the last quarter. Algert Global LLC lifted its position in shares of NovoCure by 372.2% in the third quarter. Algert Global LLC now owns 682,858 shares of the medical equipment provider’s stock worth $8,823,000 after buying an additional 538,235 shares in the last quarter. American Century Companies Inc. lifted its position in shares of NovoCure by 18.3% in the third quarter. American Century Companies Inc. now owns 1,218,807 shares of the medical equipment provider’s stock worth $15,747,000 after buying an additional 188,933 shares in the last quarter. C WorldWide Group Holding A S lifted its position in shares of NovoCure by 56.3% in the third quarter. C WorldWide Group Holding A S now owns 971,784 shares of the medical equipment provider’s stock worth $12,555,000 after buying an additional 350,000 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. purchased a new stake in shares of NovoCure in the third quarter worth about $1,085,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure Stock Performance

NVCR opened at $10.55 on Tuesday. The firm has a market cap of $1.20 billion, a P/E ratio of -8.65 and a beta of 0.82. NovoCure Limited has a 12 month low of $9.82 and a 12 month high of $20.06. The company has a current ratio of 2.90, a quick ratio of 2.71 and a debt-to-equity ratio of 0.70. The stock has a 50-day moving average of $11.88 and a 200 day moving average of $12.63.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.19. The company had revenue of $174.35 million during the quarter, compared to analyst estimates of $174.40 million. NovoCure had a negative return on equity of 39.11% and a negative net margin of 20.79%.The firm’s revenue was up 8.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.61) earnings per share. As a group, research analysts forecast that NovoCure Limited will post -1.3 EPS for the current year.

Analyst Ratings Changes

NVCR has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Wedbush reiterated a “neutral” rating and issued a $18.00 target price on shares of NovoCure in a research report on Thursday, January 15th. Evercore set a $20.00 target price on NovoCure in a research report on Monday, January 5th. Finally, HC Wainwright lifted their price target on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $26.93.

Insider Buying and Selling

In other NovoCure news, insider Uri Weinberg sold 6,412 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total value of $85,343.72. Following the completion of the sale, the insider owned 267,190 shares of the company’s stock, valued at $3,556,298.90. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman William F. Doyle sold 71,887 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $12.98, for a total transaction of $933,093.26. Following the completion of the sale, the chairman directly owned 328,397 shares of the company’s stock, valued at approximately $4,262,593.06. The trade was a 17.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 140,041 shares of company stock valued at $1,860,116 in the last quarter. 5.52% of the stock is currently owned by insiders.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.